{"product_id":"fujifilm-swot-analysis","title":"Fujifilm Holdings SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete SWOT Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eFujifilm Holdings blends resilient core imaging technologies with diversified healthcare and materials businesses, positioning it well against cyclical print markets while navigating digital disruption and supply-chain complexities.\u003c\/p\u003e\n\u003cp\u003eKey strengths include strong R\u0026amp;D, brand equity, and profitable medical imaging segments, balanced by threats from intensifying competition and slower consumer demand.\u003c\/p\u003e\n\u003cp\u003eDiscover the full SWOT analysis—purchase the complete, editable report (Word + Excel) for research-backed insights, strategic recommendations, and tools to support investment or corporate planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant CDMO Presence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFujifilm pivoted into CDMO (contract development and manufacturing organization) for biologics and by FY2024 its Life Science segment generated ¥1.05 trillion in revenue, driven largely by CDMO contracts with major pharmas; CDMO now accounts for roughly 40% of segment sales and is the primary engine for projected long-term growth into late 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Margin Imaging Brand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe imaging segment is a high-margin pillar, driven by Instax instant cameras (over 10m units shipped cumulatively by 2024) and premium X-series mirrorless bodies; these products deliver gross margins near 40% in FY2024, well above the group average.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Materials Expertise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFujifilm’s deep expertise in chemical and thin-film tech powers its dominance supplying specialty materials to semiconductors and displays; fiscal 2024 materials sales reached ¥430 billion (≈$3.1bn), up 8% YoY. As chip and advanced-screen demand rose—semiconductor equipment capex grew ~15% in 2024—Fujifilm’s supplier role tightened, boosting segment operating margin to ~12%. The proprietary, complex processes form a strong, hard-to-replicate technical moat.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust R\u0026amp;D Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFujifilm directs about 6.5% of FY2024 revenue (~¥180 billion) to R\u0026amp;D, focusing on life sciences and environmental tech, which fuels pipeline growth in regenerative medicine and cell-culture media.\u003c\/p\u003e\n\u003cp\u003eThis R\u0026amp;D intensity produced products like CELLnTEC partnerships and increased pharmaceuticals sales 12% YoY in 2024, keeping Fujifilm positioned in high-growth biotech and sustainability markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eR\u0026amp;D spend: ~¥180B (FY2024)\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D ratio: ~6.5% of revenue\u003c\/li\u003e\n\u003cli\u003ePharma sales growth: +12% YoY 2024\u003c\/li\u003e\n\u003cli\u003eKey areas: regenerative medicine, cell-culture media, environmental tech\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinancial Stability and Diversification\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpfujifilm holdings benefits from a diversified portfolio across healthcare materials and imaging which buffered revenue volatility trillion reducing single-sector risk.\u003e\n\u003cpstrong cash flows from legacy businesses flow billion in fy2024 are reinvested into biopharma and medical ai supporting r m\u003e\n\u003cpdisciplined financial management keeps net cash positive billion at mar enabling global expansion and capex without raising debt.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFY2024 operating cash flow ¥290.4B\u003c\/li\u003e\n\u003cli\u003eHealthcare revenue ~¥2.2T (FY2024)\u003c\/li\u003e\n\u003cli\u003eNet cash ¥150.3B (Mar 31, 2025)\u003c\/li\u003e\n\u003cli\u003eImaging revenue ~¥1.1T (FY2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pdisciplined\u003e\u003c\/pstrong\u003e\u003c\/pfujifilm\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFujifilm: Diversified ¥4.78T revenue base, strong CDMO life sciences \u0026amp; solid cash\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFujifilm’s strengths: diversified revenue from Healthcare ¥2.2T and Imaging ¥1.1T (FY2024), CDMO-led Life Sciences ¥1.05T with CDMO ≈40% of segment, specialty materials ¥430B (FY2024) with ~12% margin, R\u0026amp;D ~¥180B (6.5% rev), operating cash flow ¥290.4B and net cash ¥150.3B (Mar 31, 2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealthcare rev FY2024\u003c\/td\u003e\n\u003ctd\u003e¥2.2T\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImaging rev FY2024\u003c\/td\u003e\n\u003ctd\u003e¥1.1T\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLife Science rev FY2024\u003c\/td\u003e\n\u003ctd\u003e¥1.05T\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMaterials sales FY2024\u003c\/td\u003e\n\u003ctd\u003e¥430B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D FY2024\u003c\/td\u003e\n\u003ctd\u003e¥180B (6.5%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating CF FY2024\u003c\/td\u003e\n\u003ctd\u003e¥290.4B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet cash (Mar 31, 2025)\u003c\/td\u003e\n\u003ctd\u003e¥150.3B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT overview of Fujifilm Holdings, highlighting its core strengths in imaging and diversified healthcare businesses, internal challenges such as declining traditional print revenues, growth opportunities in medical imaging and digital solutions, and external threats from rapid technological change and intense competition.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, visual SWOT snapshot of Fujifilm Holdings for rapid strategy alignment and stakeholder briefings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDeclining Graphic Communications Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe graphic communications division saw revenue fall 12% year-over-year in fiscal 2024 to ¥180 billion (approx $1.3bn), as demand for offset plates and chemicals declined with digital media adoption; this structural drop now drags consolidated growth despite Fujifilm’s market share. \u003c\/p\u003e\n\u003cp\u003eExecutive management must reallocate capex and cut fixed costs while shifting product mix to digital printing and services to protect margins; margin compression in the segment narrowed operating profit by ~240 basis points in 2024. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeavy Capital Expenditure Requirements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe shift into biopharma needs huge, ongoing capex for specialized plants and single‑use bioreactors; Fujifilm reported capital expenditures of JPY 183.4 billion in FY2024, a large share tied to bioprocessing expansions.\u003c\/p\u003e\n\u003cp\u003eSuch spending can strain liquidity and raise leverage—Fujifilm’s net debt rose to about JPY 450 billion by March 2025—heightening refinancing and covenant risk.\u003c\/p\u003e\n\u003cp\u003eLong build and validation times (often 18–36 months) delay cash flow, so project timing sensitivity increases financial risk and ROI uncertainty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComplexity in Multi-Sector Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOperating across healthcare, office solutions, and imaging adds heavy complexity—Fujifilm Holdings reported ¥2.7 trillion revenue in FY2024 (year ended Mar 31, 2024) across segments, forcing slow, layered decision-making that delayed a 2023 global product rollout by six months.\u003c\/p\u003e\n\u003cp\u003eCross-departmental synergies suffer: only 8% of FY2024 R\u0026amp;D (¥84.6 billion) was centrally allocated, hindering unified platform development and increasing duplication. \u003c\/p\u003e\n\u003cp\u003eAligning disparate units demands vast oversight—corporate SG\u0026amp;A rose 7.4% YoY to ¥240 billion in FY2024, reflecting added management resources and integration costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVulnerability to Raw Material Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFujifilm’s manufacturing uses costly inputs like silver, aluminum and speciality chemicals; silver prices rose ~14% in 2024, squeezing imaging and electronics margins.\u003c\/p\u003e\n\u003cp\u003eCommodity swings feed through to COGS, compressing consolidated operating margin (FY2024 operating margin 6.8%); supply-chain bottlenecks raise freight\/input premiums unpredictably.\u003c\/p\u003e\n\u003cp\u003eGlobal supplier reliance means logistics shocks or tariff shifts can raise costs beyond Fujifilm’s hedges and pricing power.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSilver exposure—price +14% in 2024\u003c\/li\u003e\n\u003cli\u003eFY2024 operating margin 6.8%\u003c\/li\u003e\n\u003cli\u003eHigh share of imported inputs—logistics risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrand Association with Legacy Film\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpdespite transforming into a healthcare and materials leader of fy2024 revenue came from highly functional ended mar still faces public investor association with photographic film which can obscure its high-tech credentials.\u003e\u003cpthis legacy perception can deter specialized talent and partners seeking biotech or advanced materials expertise forcing ongoing rebranding spend fujifilm reported billion in advertising promotion costs fy2024.\u003e\u003cpovercoming this branding lag requires sustained costly marketing and stakeholder engagement to align corporate identity with its r portfolio.\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e53% FY2024 revenue: healthcare\/materials\u003c\/li\u003e\n\u003cli\u003e¥39.6B FY2024 advertising spend\u003c\/li\u003e\n\u003cli\u003eLegacy image risks partner\/talent attraction\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/povercoming\u003e\u003c\/pthis\u003e\u003c\/pdespite\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh capex, rising debt and shrinking graphic revenues squeeze margins and brand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eWeaknesses: legacy imaging drag on brand; heavy capex for biopharma (JPY183.4B FY2024) raising net debt (≈JPY450B Mar‑2025) and project timing risk (18–36 months); shrinking graphic-communications revenue (‑12% FY2024 to JPY180B) compressing margins (operating margin 6.8% FY2024); commodity exposure (silver +14% 2024) and high SG\u0026amp;A (JPY240B FY2024) add cost pressure.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex FY2024\u003c\/td\u003e\n\u003ctd\u003eJPY183.4B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt Mar‑2025\u003c\/td\u003e\n\u003ctd\u003e≈JPY450B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGraphic rev FY2024\u003c\/td\u003e\n\u003ctd\u003eJPY180B (‑12%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating margin FY2024\u003c\/td\u003e\n\u003ctd\u003e6.8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSilver price 2024\u003c\/td\u003e\n\u003ctd\u003e+14%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eFujifilm Holdings SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003cp\u003eThe preview below is taken directly from the full SWOT report you'll get. Purchase unlocks the entire in-depth version.\u003c\/p\u003e\n\u003cp\u003eThis is a real excerpt from the complete document. Once purchased, you’ll receive the full, editable version.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752206119289,"sku":"fujifilm-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/fujifilm-swot-analysis.png?v=1772238350","url":"https:\/\/growthsharematrix.com\/products\/fujifilm-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}